ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors

PURPOSE: This study aimed to identify biomarkers of resistance to endocrine therapy in ER+ breast cancers (BC) treated with prolonged neoadjuvant letrozole. EXPERIMENTAL DESIGN: We performed targeted DNA and RNA-sequencing in 68 ER+ BC from patients treated with preoperative letrozole (median 7 mont...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Guerrero-Zotano, Angel L., Stricker, Thomas P., Formisano, Luigi, Hutchinson, Katherine E., Stover, Daniel G., Lee, Kyung-min, Schwarz, Luis J., Giltnane, Jennifer M., Estrada, Valeria M., Jansen, Valerie M., Servetto, Alberto, Gavilá, Joaquín, Perez-Fidalgo, J. Alejandro, Lluch, Ana, Llombart, Antonio, Bayar, Mohamed A., Michiels, Stefan, André, Fabrice, Arnedos, Mónica, Guillem, Vicente, Ruiz, Amparo, Arteaga, Carlos L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690756/
https://ncbi.nlm.nih.gov/pubmed/29581135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2904
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller